Heng Luo

5.2k total citations
90 papers, 2.3k citations indexed

About

Heng Luo is a scholar working on Molecular Biology, Computational Theory and Mathematics and Pharmacology. According to data from OpenAlex, Heng Luo has authored 90 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 20 papers in Computational Theory and Mathematics and 17 papers in Pharmacology. Recurrent topics in Heng Luo's work include Computational Drug Discovery Methods (20 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Bioinformatics and Genomic Networks (7 papers). Heng Luo is often cited by papers focused on Computational Drug Discovery Methods (20 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Bioinformatics and Genomic Networks (7 papers). Heng Luo collaborates with scholars based in China, United States and Malaysia. Heng Luo's co-authors include Ping Zhang, Lun Yang, Huixiao Hong, Lin He, Sanjoy Kumer Dey, Achille Fokoue, Weida Tong, Hui Wen Ng, Kun Wang and Leming Shi and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Angewandte Chemie International Edition.

In The Last Decade

Heng Luo

86 papers receiving 2.3k citations

Peers

Heng Luo

CTM

PHARM

Weilin Zhang China

Shiwei Wang China

Luca Pinzi Italy

Weiqiang Lü China

Ningning Wang China

Xiaofeng Liu China

Ricardo Nascimento dos Santos Brazil

Alexey Zakharov United States

Chengkun Wu China

Matthias Wirth Germany

Weilin Zhang China

Heng Luo

972 ×0.9

602 ×0.8

CTM

233 ×0.6

PHARM

260 ×1.0

PHARM

196 ×0.8

Citations per year, relative to Heng Luo Heng Luo (= 1×) peers Weilin Zhang

Countries citing papers authored by Heng Luo

Since Specialization

Citations

This map shows the geographic impact of Heng Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Luo more than expected).

Fields of papers citing papers by Heng Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Luo. The network helps show where Heng Luo may publish in the future.

Co-authorship network of co-authors of Heng Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Heng Luo. A scholar is included among the top collaborators of Heng Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Luo. Heng Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Jia, Yunyun Zhou, Huimin Li, et al.. (2024). Quinazoline derivatives inhibit cell growth of prostate cancer as a WRN helicase dependent manner by regulating DNA damage repair and microsatellite instability. Bioorganic Chemistry. 153. 107963–107963. 5 indexed citations

Luo, Zhongwen, Shang Li, Yonglei Zhang, et al.. (2023). Oxazole-4-carboxamide/butylated hydroxytoluene hybrids with GSK-3β inhibitory and neuroprotective activities against Alzheimer's disease. European Journal of Medicinal Chemistry. 256. 115415–115415. 9 indexed citations

Li, Xinxin, Cheng Wang, Shang Li, et al.. (2023). Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy. European Journal of Medicinal Chemistry. 265. 116054–116054. 11 indexed citations

Zhang, Ting, et al.. (2023). Research Progress on the Anticancer Molecular Mechanism of Targets Regulating Cell Autophagy. Pharmacology. 108(3). 224–237. 12 indexed citations

Wang, Cheng, Heng Luo, Xinye Chen, et al.. (2023). Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA. Bioorganic Chemistry. 139. 106683–106683. 11 indexed citations

Chen, Xinye, Cheng Wang, Dehua Lu, et al.. (2023). Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry. 91. 117386–117386. 6 indexed citations

Wang, Cheng, Xinye Chen, Xingchen Liu, et al.. (2022). Discovery of precision targeting EZH2 degraders for triple-negative breast cancer. European Journal of Medicinal Chemistry. 238. 114462–114462. 38 indexed citations

Guo, Ya, et al.. (2021). Identification of Three Autophagy-Related Long Non-Coding RNAs as a Novel Head and Neck Squamous Cell Carcinoma Prognostic Signature. Frontiers in Oncology. 10. 603864–603864. 14 indexed citations

Liu, Xiaobin, et al.. (2020). Machine‐Learning Prediction of Oral Drug‐Induced Liver Injury (DILI) via Multiple Features and Endpoints. BioMed Research International. 2020(1). 4795140–4795140. 12 indexed citations

10.

Yang, Huali, Xiaobing Wang, Cheng Wang, et al.. (2020). Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer. European Journal of Medicinal Chemistry. 210. 113080–113080. 15 indexed citations

11.

Zhang, Mingfeng, et al.. (2019). Isoorientin alleviates UVB-induced skin injury by regulating mitochondrial ROS and cellular autophagy. Biochemical and Biophysical Research Communications. 514(4). 1133–1139. 37 indexed citations

12.

Dey, Sanjoy Kumer, Heng Luo, Achille Fokoue, Jianying Hu, & Ping Zhang. (2018). Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics. 19(S21). 476–476. 108 indexed citations

13.

Zhang, Meng, Yifei Jiang, Yong Liu, et al.. (2017). Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China.. PubMed. 23(127). 207–219. 42 indexed citations

14.

Ye, Hao, Heng Luo, Hui Wen Ng, et al.. (2016). Applying network analysis and Nebula (neighbor-edges based and unbiased leverage algorithm) to ToxCast data. Environment International. 89-90. 81–92. 6 indexed citations

15.

Yang, Ying, Feng Yang, Gil Alterovitz, et al.. (2016). HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. The Pharmacogenomics Journal. 17(6). 501–505. 12 indexed citations

16.

Ng, Hui Wen, Mao Shu, Heng Luo, et al.. (2015). Comparing genetic variants detected in the 1000 genomes project with SNPs determined by the International HapMap Consortium. Journal of Genetics. 94(4). 731–740. 12 indexed citations

17.

Yang, Feng, Jiekun Xuan, Jinlong Chen, et al.. (2015). HLA-B*59:01: a marker for Stevens–Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. The Pharmacogenomics Journal. 16(1). 83–87. 42 indexed citations

18.

Zhou, Chensheng W., et al.. (2012). FOLDNA, a Web Server for Self-Assembled DNA Nanostructure Autoscaffolds and Autostaples. SHILAP Revista de lepidopterología. 2012. 1–5. 4 indexed citations

19.

Yang, Lun, Kun Wang, Jian Chen, et al.. (2011). Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study. PLoS Computational Biology. 7(3). e1002016–e1002016. 90 indexed citations

20.

Yang, Lun, Heng Luo, Jian Chen, Qinghe Xing, & Lin He. (2009). SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome. Nucleic Acids Research. 37(suppl_2). W406–W412. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact